ABBV
AbbVie Inc.NYSEHealthcare$208.79-2.88%OpenMarket Cap: $369.19B
As of 2026-04-06
Valuation
P/E (TTM)
87.36
PEG
—
P/B
-113.68
P/S
6.04
EV/EBITDA
15.30
DCF Value
$162.20
FCF Yield
5.1%
Div Yield
3.2%
Margins & Returns
Gross Margin
73.3%
Operating Margin
26.7%
Net Margin
6.9%
ROE
-361.6%
ROA
9.3%
ROIC
10.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $16.62B | 84.0% | $5.81B | $1.82B | $1.02 | $1.64 |
| FY 2025 | $61.16B | 83.7% | $21.21B | $4.23B | $2.36 | $6.56 |
| Q3 2025 | $15.78B | 66.4% | $1.90B | $186.0M | $0.10 | $1.64 |
| Q2 2025 | $15.42B | 71.8% | $4.89B | $938.0M | $0.53 | $1.64 |
| Q1 2025 | $13.34B | 70.0% | $3.73B | $1.29B | $0.72 | $1.64 |
| Q4 2024 | $15.10B | 70.9% | $-1.49B | $-22.0M | $-0.02 | $1.55 |
| FY 2024 | $56.33B | 70.0% | $9.14B | $4.28B | $2.39 | $6.20 |
| Q3 2024 | $14.46B | 70.9% | $3.83B | $1.56B | $0.88 | $1.55 |
| Q2 2024 | $14.46B | 70.9% | $4.00B | $1.37B | $0.77 | $1.55 |
| Q1 2024 | $12.31B | 66.7% | $2.80B | $1.37B | $0.77 | $1.55 |
| Q4 2023 | $14.30B | 60.1% | $3.19B | $822.0M | $0.46 | $1.48 |
| FY 2023 | $54.32B | 62.4% | $12.76B | $4.86B | $2.72 | $5.92 |